Data from Phase III trial of MK 5172 + MK 8742 (grazoprevir/elbasvir) in HCV published-Merck Inc
Merck Inc has announced the first data from the ongoing C-EDGE pivotal Phase III clinical trial program evaluating the investigational once-daily tablet MK 5172+MK 8742 (grazoprevir/elbasvir) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6). Patients in both the HCV infected, treatment-na�ve (C-EDGE TN), and HIV/HCV co-infected, treatment-na�ve (C-EDGE CO-INFXN) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299/316 and 207/218, respectively).
In addition, HCV infected, treatment-experienced patients (C-EDGE TE) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98/104) and 92 percent (97/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103/106) and 92 percent (97/105), respectively. These data were presented at The International Liver Congress 2015. A paper detailing the findings of C-EDGE TN was published online in the Annals of Internal Medicine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins